Recombinant protein vaccines, a proven approach against coronavirus pandemics
With the COVID-19 pandemic now ongoing for close to a year, people all over the world are
still waiting for a vaccine to become available. The initial focus of accelerated global …
still waiting for a vaccine to become available. The initial focus of accelerated global …
[PDF][PDF] Aging and the immune system: the impact of immunosenescence on viral infection, immunity and vaccine immunogenicity
CX Chan, YO Yang, GHM Cheng, SK Gera… - Immune …, 2019 - synapse.koreamed.org
Background Prophylactic pinning of the uninvolved side after unilateral slipped capital
femoral epiphysis (SCFE) is controversial. The alpha angle, a measurement of femoral head …
femoral epiphysis (SCFE) is controversial. The alpha angle, a measurement of femoral head …
Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine
KJ Hager, G Pérez Marc, P Gobeil… - New England journal …, 2022 - Mass Medical Soc
Abstract Background Coronavirus-like particles (CoVLP) that are produced in plants and
display the prefusion spike glycoprotein of the original strain of severe acute respiratory …
display the prefusion spike glycoprotein of the original strain of severe acute respiratory …
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
BJ Ward, P Gobeil, A Séguin, J Atkins, I Boulay… - Nature medicine, 2021 - nature.com
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being
deployed, but the global need greatly exceeds the supply, and different formulations might …
deployed, but the global need greatly exceeds the supply, and different formulations might …
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
PS Arunachalam, AC Walls, N Golden, C Atyeo… - Nature, 2021 - nature.com
The development of a portfolio of COVID-19 vaccines to vaccinate the global population
remains an urgent public health imperative. Here we demonstrate the capacity of a subunit …
remains an urgent public health imperative. Here we demonstrate the capacity of a subunit …
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind …
P Richmond, L Hatchuel, M Dong, B Ma, B Hu… - The lancet, 2021 - thelancet.com
Background As part of the accelerated development of vaccines against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant …
respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant …
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
R Nachbagauer, J Feser, A Naficy, DI Bernstein… - Nature medicine, 2021 - nature.com
Seasonal influenza viruses constantly change through antigenic drift and the emergence of
pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza …
pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza …
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer …
Background Vaccination has helped to mitigate the COVID-19 pandemic. Ten traditional and
novel vaccines have been listed by the World Health Organization for emergency use …
novel vaccines have been listed by the World Health Organization for emergency use …
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …
PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
“World in motion”–emulsion adjuvants rising to meet the pandemic challenges
Emulsion adjuvants such as MF59 and AS03 have been used for more than two decades as
key components of licensed vaccines, with over 100 million doses administered to diverse …
key components of licensed vaccines, with over 100 million doses administered to diverse …